ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Few biomedical research projects are being delayed or abandoned because of intellectual property restrictions, concludes a study by the National Academies. That report, “Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights,” points out, however, that this situation may change as the patent picture becomes more complex. To avoid future legal problems, the report recommends that scientists and institutions follow best practices guidelines already available from, for example, NIH and the National Research Council, on patenting genes and proteins. The report calls on Patent & Trademark Office examiners to stay current with the scientific and clinical developments in the field. Steps should also be taken to protect researchers from infringement liability when working on patented inventions in this area. “The goal is to ensure that public investments in genomics and proteomics bring about the greatest public good,” said report committee cochair Shirley M. Tilghman, president of Princeton University. “In aiming for that goal, researchers, policymakers, and other stakeholders must recognize that achieving an appropriate balance between protecting research discoveries and granting access to them is critically important to fostering scientific progress and enhancing human health.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter